Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 1:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 113 matching trials from the live ClinicalTrials.gov search.
Conditions
Women's Health, Obesity & Overweight, Perimenopausal Women, Digital Intervention, Behavior Change, glp1 Agonist, Resistance Exercise
Interventions
PLAN-RT 1.0
Behavioral
Lead sponsor
Louisiana State University and A&M College
Other
Eligibility
40 Years to 59 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
glp1 Agonist, Gene Expression, Skin Laxity
Interventions
ellacor
Device
Lead sponsor
Cytrellis Biosystems, Inc.
Industry
Eligibility
30 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Dublin, California
Completed Phase 4 Interventional Results available

Impact of Semaglutide on CD34+ EPC and Fat Derived MSC

NCT04126603
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide, Placebos
Drug
Lead sponsor
Sabyasachi Sen
Other
Eligibility
20 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Conditions
Cystic Fibrosis, Pancreatic Insufficiency, Abnormal Glucose Tolerance, Diabetes
Interventions
Dulaglutide 0.75Mg/0.5Ml Inj Pen
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania
Conditions
Weight Loss
Interventions
High protein diet, Resistance Training (RT) Programs
Other · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
30 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Spinal Cord Injuries, Type 2 Diabetes
Interventions
Semaglutide Injectable Product, Placebo
Drug · Other
Lead sponsor
Marzieh Salehi
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
San Antonio, Texas
Conditions
Autosomal Dominant Polycystic Kidney, Obesity
Interventions
Tirzepatide, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Overweight and Obesity
Interventions
24-hour ambulatory blood pressure, Liberal salt diet
Diagnostic Test · Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Obesity
Interventions
Medically tailored meals, Noom®, Usual care
Other · Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Active, not recruiting No phase listed Observational Accepts healthy volunteers

CRAVE Study: Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist Users

NCT06467604
Conditions
Obesity
Interventions
Surveys, Indirect Calorimetry, Body composition, Anthropometrics
Behavioral · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Needham, Massachusetts
Recruiting No phase listed Observational Accepts healthy volunteers

Gestational Response, Outcomes, and Weight After GLP-1 Use

NCT07743567
Conditions
Pregnant Individuals, Obesity & Overweight, Gestational Weight Gain
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Obesity, Body Composition
Interventions
Smartwatch activity and body composition monitor, General guidance on recommended exercise
Device · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Pen auto-injector, Exenatide, Prefilled pen injector, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
639 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
Interventions
Tirzepatide
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Elizabeth, New Jersey • Hamilton, New Jersey • Livingston, New Jersey + 4 more
Conditions
Type 2 Diabetes
Interventions
Tirzepatide, Semaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
51
States / cities
Birmingham, Alabama • Sheffield, Alabama • Huntington Park, California + 45 more
Conditions
Pulmonary Aspiration
Interventions
GLP-1 RA users with prolonged fasting instructions, GLP-1 RA users with standard NPO instructions
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Obesity
Interventions
GLP-1 receptor agonist, Gastric Bypass Surgery (laparoscopic), Gastric Bypass Surgery (robotic)
Drug · Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
60 participants
Timeline
2025 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Obesity or Overweight
Interventions
RGT001-075, Placebo Comparator
Drug
Lead sponsor
Regor Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
35
States / cities
Mobile, Alabama • Phoenix, Arizona • Huntington Park, California + 31 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Semaglutide Use in Elderly Obese Patients

NCT05302596
Conditions
Obesity, Aging
Interventions
Semaglutide Pen Injector
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
65 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Buffalo, New York
Completed Phase 2 Interventional Accepts healthy volunteers Results available

GPR119 Agonist for Hypoglycemia in Type 1 Diabetes

NCT04432090
Conditions
Diabetes Mellitus, Type 1
Interventions
Placebo, Study Medication (MBX-2982), No medication for this group
Drug · Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
20 Years to 60 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Alcohol Use Disorder
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
622 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
19
States / cities
Long Beach, California • Palo Alto, California • West Los Angeles, California + 15 more
Completed Phase 1Phase 2 Interventional Results available

Use of a GLP-1R Agonist to Treat Opioid Use Disorder

NCT04199728
Conditions
Opiate Substitution Treatment, Opioid-Related Disorders
Interventions
Liraglutide Pen Injector, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Conditions
Pouch, Ileal, Pouches, Ileoanal, Bowel Diseases, Inflammatory
Interventions
Tirzepatide, Loperamide, Diphenoxylate/Atropine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Beverly Hills, California • Rochester, Minnesota • St Louis, Missouri + 2 more
Conditions
Gastric Content Aspiration
Interventions
Esophagogastroduodenoscopy
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina